Oral protein drug developer secures $3M; Nektar gains fast-track status for pain drug;

@FierceBiotech: Check out this special report from @RyanMFierce: 5 next-gen software tools for biopharma R&D. Report | Follow @FierceBiotech

@RyanMFierce: Hi all, we're about to launch FierceBiotech's Fierce 15 biotech search. Countdown from 10... Survey | Follow @RyanMFierce

> Ohio-based Navidea Biopharmaceuticals has expanded to Andover, MA, north of Boston. Report

> Modulation Therapeutics has garnered a $500,000 award from The Multiple Myeloma Research Foundation as the company works on its lead drug candidate called MTI-101 for myeloma. Release

> Inclinix and PMG Research combine to boost trial enrollment business. Item

> Newton, MA, biotech Chiasma, a developer of oral peptide and protein drugs, has landed $3 million in debt financing. Report

Pharma News

@FiercePharma: India's Aurobindo hopes an FDA inspection this summer will lift import ban on antibiotics plant. More | Follow @FiercePharma

> FDA to again consider making hydrocodone combos class II drugs. More

> Missed forecast by Roche leads to Boniva shortage. News

> Novartis in tax fight over vaccine plant that HHS helped pay for. Story

> GSK extends $2.6 billion bid for Human Genome Sciences. Article

Medical Device News

@FierceMedDev: Get your nominations in for the 15 fiercest private medical device developers while there is still time. Survey | Follow @FierceMedDev

> Pressure turns to Senate after House passes device tax repeal bill. Story

> Orthofix will cough up $42M to settle kickback. News

> Open source coding could make medical devices safer. Article

> Edwards wins FDA nod to commence heart valve treatment tech clinical trial. More

And Finally… The FDA has granted fast track status to Nektar Therapeutics for the company's developmental pain drug NKTR-181. Article

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.